Su1602: ADVERSE EVENTS IN FECAL MICROBIOTA TRANSPLANTATION–A SYSTEMATIC REVIEW AND META-ANALYSIS

Rapoport, Eliot; Baig, M. A.; Puli, Srinivas R.

doi:10.1016/s0016-5085(22)61524-5

Cited by 7 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A small trial found that FMT may be more successful at eradicating VRE carriage compared to CRE carriage [102]. However, FMT is not a risk-free procedure; whilst in most cases of FMT the adverse events are relatively minor, such as gastrointestinal discomfort [108], a much more serious consequence is the risk of transferring opportunistic pathogens, which may be carried asymptomatically by donors. Infections with Shiga toxin-producing E. coli and enteropathogenic E. coli have been reported following FMT pathogen screening, which impacts the viability of FMT by increasing costs and reducing the donor pool [109].…”

Section: Harnessing Nutrient Competition To Restrict Intestinal Growt...mentioning

confidence: 99%

Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization

et al. 2023

View full text Add to dashboard Cite

The human gut microbiota can restrict the growth of pathogens to prevent them from colonizing the intestine (‘colonization resistance’). However, antibiotic treatment can kill members of the gut microbiota (‘gut commensals’) and reduce competition for nutrients, making these nutrients available to support the growth of pathogens. This disturbance can lead to the growth and expansion of pathogens within the intestine (including antibiotic-resistant pathogens), where these pathogens can exploit the absence of competitors and the nutrient-enriched gut environment. In this review, we discuss nutrient competition between the gut microbiota and pathogens. We also provide an overview of how nutrient competition can be harnessed to support the design of next-generation microbiome therapeutics to restrict the growth of pathogens and prevent the development of invasive infections.

show abstract

Section: Harnessing Nutrient Competition To Restrict Intestinal Growt...mentioning

confidence: 99%

Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In einer Auswertung der Nebenwirkungen, bei der mehr als 5000 Menschen inkludiert waren, zeigten weniger als 1% schwere Nebenwirkungen. Diese waren Septikämien, Aspiration des Transplantats und Perforation des Darms bei Eingabe des Transplantats 10 . Milde Nebenwirkungen wurden ebenfalls nur selten beobachtet und waren selbstlimitierend.…”

Section: Mögliche Risikenunclassified

“…Milde Nebenwirkungen wurden ebenfalls nur selten beobachtet und waren selbstlimitierend. Zu diesen gehörten abdominale Dolenz, Nausea und Vomitus, Obstipation sowie Fieber 10 . In der Veterinärmedizin sind nur Einzelfallberichte zu Komplikationen bei Kottransplantationen veröffentlicht.…”

Section: Mögliche Risikenunclassified

Braunes Gold – Kottransplantation als Therapieoption beim Hund

Dinkel,

Dahlem

2024

kleintier konkret

View full text Add to dashboard Cite

“…The favorable tolerability profile of VE303 was expected, based on prior reports of fecal microbiota transplants and other live biotherapeutic products. 12,13,22,23 The VE303 component strains colonized rapidly during the dosing period. VE303 strains showed significantly greater abundance and prevalence in both of the VE303 groups compared with placebo.…”

Section: Limitationsmentioning

confidence: 99%

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection

Louie

Golan

Khanna

et al. 2023

JAMA

View full text Add to dashboard Cite

ImportanceThe effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of Clostridioides difficile infection (CDI) is unknown.ObjectiveTo determine the efficacy of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, in adults at high risk for CDI recurrence. The primary objective was to determine the recommended VE303 dosing for a phase 3 trial.Design, Setting, and ParticipantsPhase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 to September 2021 at 27 sites in the US and Canada. The study included 79 participants aged 18 years or older who were diagnosed with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence (defined as aged ≥75 years or ≥65 years with ≥1 risk factors: creatinine clearance &lt;60 mL/min/1.73 m2, proton pump inhibitor use, remote [&gt;6 months earlier] CDI history).InterventionsParticipants were randomly assigned to high-dose VE303 (8.0 × 109 colony-forming units [CFUs]) (n = 30), low-dose VE303 (1.6 × 109 CFUs) (n = 27), or placebo capsules (n = 22) orally once daily for 14 days.Main Outcomes and MeasuresThe primary efficacy end point was the proportion of participants with CDI recurrence at 8 weeks using a combined clinical and laboratory definition. The primary efficacy end point was analyzed in 3 prespecified analyses, using successively broader definitions for an on-study CDI recurrence: (1) diarrhea consistent with CDI plus a toxin-positive stool sample; (2) diarrhea consistent with CDI plus a toxin-positive, polymerase chain reaction–positive, or toxigenic culture–positive stool sample; and (3) diarrhea consistent with CDI plus laboratory confirmation or (in the absence of a stool sample) treatment with a CDI-targeted antibiotic.ResultsBaseline characteristics were similar across the high-dose VE303 (n = 29; 1 additional participant excluded from efficacy analysis), low-dose VE303 (n = 27), and placebo (n = 22) groups. The participants’ median age was 63.5 years (range, 24-96); 70.5% were female; and 1.3% were Asian, 1.3% Black, 2.6% Hispanic, and 96.2% White. CDI recurrence rates through week 8 (using the efficacy analysis 3 definition) were 13.8% (4/29) for high-dose VE303, 37.0% (10/27) for low-dose VE303, and 45.5% (10/22) for placebo (P = .006, high-dose VE303 vs placebo).Conclusions and RelevanceAmong adults with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.Trial RegistrationClinicalTrials.gov Identifier: NCT03788434

show abstract

Su1602: ADVERSE EVENTS IN FECAL MICROBIOTA TRANSPLANTATION–A SYSTEMATIC REVIEW AND META-ANALYSIS

Cited by 7 publications

References 0 publications

Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization

Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization

Braunes Gold – Kottransplantation als Therapieoption beim Hund

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection

Contact Info

Product

Resources

About